Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5470]
News [12772]
Articles [183]
Editorials [5]
Conferences [249]
elearning [17]
SABCS 2019: Combining atezolizumab with neoadjuvant chemotherapy does not improve pathologic complete response rates for patients with triple-negative breast cancer
SABCS 2019: Combining atezolizumab with neoadjuvant chemotherapy does not improve pathologic complete response...
SABCS 2019: Addition of S-1 to post-operative endocrine therapy improves outcomes for patients with hormone receptor-positive, HER2-negative breast cancer
SABCS 2019: Addition of S-1 to post-operative endocrine therapy improves outcomes for patients with hormone...
SABCS 2019: New HER2 antibody-drug conjugate yielded promising clinical responses in breast cancer patients pretreated with T-DM1
SABCS 2019: New HER2 antibody-drug conjugate yielded promising clinical responses in breast cancer patients...
ASH 2019: New drug markedly improves overall survival in patients with AML in remission
ASH 2019: New drug markedly improves overall survival in patients with AML in remission
ASH 2019: Study reveals genetic underpinnings of AML and myelodysplastic syndrome
ASH 2019: Study reveals genetic underpinnings of AML and myelodysplastic syndrome
ASH 2019: Triple drug combination delays disease progression in people with stubborn multiple myeloma
ASH 2019: Triple drug combination delays disease progression in people with stubborn multiple myeloma
ASH 2019: Immunotherapy superior to chemotherapy for children with relapsed B-ALL
ASH 2019: Immunotherapy superior to chemotherapy for children with relapsed B-ALL
ASH 2019: Daratumumab shows overall survival benefit and continued improvement in progression-free survival in patients with newly diagnosed multiple myeloma who are ineligible for transplant
ASH 2019: Daratumumab shows overall survival benefit and continued improvement in progression-free survival in...
Anti-CTLA-4 antibody tremelimumab shows efficacy in patients with metastatic bladder cancer
Anti-CTLA-4 antibody tremelimumab shows efficacy in patients with metastatic bladder cancer
ASH 2019: Combination therapy aimed at slowing the progression of a precursor myeloma condition
ASH 2019: Combination therapy aimed at slowing the progression of a precursor myeloma condition

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation